Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer

Adenocarcinoma of the Colon Clinical Trial

— PERIOP-01  

Official title:

A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01455831
• Other study ID #: 221097
• Status: Completed
• Phase: Phase 3
• Start date: September 2011
• Est. completion date: February 1, 2021

Study information

• Verified date: May 2021
• Source: Ottawa Hospital Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The human body has a natural stress response to surgery, including the formation of blood clots. This response to surgery has been shown to increase metastases (the spread of cancer cells to other organs in the body). These metastases cannot be seen at the time of surgery but when they grow into new tumors, the cancer has recurred (come back). A blood thinner called "low molecular weight heparin" (LMWH) can suppress the development of metastases after surgery in animal experiments. The investigators want to see if giving patients with colorectal cancer the blood thinner, LMWH, around the time of surgery can decrease the chance of their cancer spreading to other organs (metastases) and coming back (recurrence).

The investigators need 1075 patients to answer our scientific question. Patients who give informed consent will be randomly put into one of two groups, the experimental group and the control group. The patients in the control group will be treated with LMWH starting a few hours after surgery and every day until they leave the hospital. This is how most patients are treated after colon cancer surgery (standard care). The patients in the experimental group will be treated with LMWH for a longer period of time, starting on the day they agree to have surgery and continuing for two months after surgery. All the patients will be followed for at least three years after surgery to find out if their cancer has recurred (come back). If LMWH treatment around the time of surgery reduces the chance of recurrence in patients with colorectal cancer, it would improve the health and quality of life for these patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 616
• Est. completion date: February 1, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosis of pathologically-confirmed invasive adenocarcinoma of the colon or rectum

2. Pre-operative work-up that reveals potential resectability (CT scan or MRI of the abdomen and pelvis) with resection planned within 6 weeks of date of randomization

3. Pre-operative work-up that reveals no evidence of metastatic disease (CT scan or MRI of the abdomen and pelvis and chest X-ray (CXR) or CT scan of the chest)

4. Age =18 years

5. Hemoglobin = 80g/L

6. Able and willing to comply with study procedures and follow-up examinations contained within the written consent form.

Exclusion Criteria:

1. Carcinoma only present in a completely excised polyp (i.e. no residual tumour evident in the colon)

2. Prior VTE including deep vein thrombosis (DVT) or pulmonary embolism (PE)

3. Requirement for full dose peri-operative anticoagulation

4. Contraindication to heparin therapy

1. history of heparin induced thrombocytopenia (HIT)

2. platelet count of less than 100 x 109/L

3. actively bleeding

4. severe hypertension (SBP >200 and/or DBP >120) on more than one reading

5. documented peptic ulcer within 6 weeks

6. severe hepatic failure (INR >1.8)

7. creatinine clearance of < 30 ml/min as calculated by the Cockcroft-Gault formula

8. Other contraindication to anticoagulation

5. Participating in another interventional trial that may result in co-intervention or contamination (to be determined by sponsor)

6. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years of the colorectal cancer diagnosis

7. Pregnant or lactating

8. Unable/unwilling to providing informed consent.

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of the Colon
• Colorectal Neoplasms

Intervention

Drug:
• Tinzaparin
The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
• Tinzaparin
The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.

Locations

Country	Name	City	State
Belgium	Ghent University Hospital	Ghent
Canada	Hamilton Health Sciences Corporation	Hamilton	Ontario
Canada	Kingston General Hospital	Kingston	Ontario
Canada	London Health Research Institute	London	Ontario
Canada	Jewish General Hospital	Montreal	Quebec
Canada	Montfort Hospital	Ottawa	Ontario
Canada	Queensway Carleton Hospital	Ottawa	Ontario
Canada	The Ottawa Hospital	Ottawa	Ontario
Canada	Sault Area Hospital	Sault Ste. Marie	Ontario
Canada	Health Sciences North	Sudbury	Ontario
Canada	Humber River Hospital	Toronto	Ontario
Canada	Mount Sinai Hospital	Toronto	Ontario
Canada	North York General Hospital	Toronto	Ontario
Canada	St. Joseph's Health Centre	Toronto	Ontario
Canada	Sunnybrook Health Science Centre	Toronto	Ontario
France	CHRU Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute

Countries where clinical trial is conducted

Belgium,  Canada,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Free Survival	Disease free survival is measured from the time of randomization until local disease recurrence, distant disease recurrence, a new primary colon cancer malignancy, other second primary cancer or death from any cause.	measured at 3 years
Secondary	Overall Survival	Death from any cause	measured at 5 years
Secondary	Venous Thromboembolism events	• VTE events defined as: a. Deep vein thrombosis: i. non-compressibility of any vein segment from the common femoral vein to the trifurcation of the popliteal vein on compressive ultrasonography ii.persistent intra-luminal filling defect of the iliac, common femoral, superficial femoral, popliteal, posterior tibial or peroneal veins on contrast venography b. Pulmonary embolism: i.high probability V/Q scan ii.positive pulmonary angiogram iii.spiral CT demonstrating intraluminal filling defect in a vessel larger than a segmental artery	From randomization until 56 days post-surgery
Secondary	Major surgical site bleeding events	• Major surgical site bleeding events defined as bleeding at the surgical site associated with: requirement for =4 units of packed red blood cells; a drop in Hb of >40 g/L during the first post-op week; bleeding requiring re-operation; fatal bleeding	From randomization until 56 days post-surgery
Secondary	Major bleeding events (not including the surgical site)	• Major bleeding events (not including the surgical site) defined as: fatal bleeding, and/or; symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or,; bleeding causing a fall in hemoglobin level of =20 g/L, or leading to transfusion of =2 units of whole blood or red cells.	From randomization until 56 days post-surgery
Secondary	• Clinically relevant bleeding events prior to surgery and during the • Clinically relevant bleeding events	Clinically relevant bleeding events prior to surgery and during the follow-up period will be defined as overt bleeding episodes not meeting the inclusion for major bleeding but associated with one of the following: medical intervention; an unscheduled contact with a physician; temporary cessation of anticoagulant treatment	From randomization to 56 days post-surgery
Secondary	Transfusion requirements	Transfusion requirements using the number of units transfused: Red blood cells; Platelets (Adult dose); Frozen Plasma	From randomization to 56 days post-surgery
Secondary	Correlative endpoints	The correlative endpoints seek to evaluate the pro-metastatic mechanisms of surgery and the antimetastatic mechanisms of LMWH in subjects undergoing surgical resection for colon cancer.	5 years
Secondary	Other post-operative (day 0 - day 28) complications	Other post-operative (day 0 - day 28) complications as defined using the modified Clavien Classification	Measured from Day 0 until day 28 post-operatively